DaVita (NYSE:DVA) Price Target Raised to $169.00

DaVita (NYSE:DVA) had its price target boosted by Barclays from $164.00 to $169.00 in a research report released on Tuesday morning,Benzinga reports. Barclays currently has an equal weight rating on the stock.

DaVita Price Performance

Shares of NYSE DVA opened at $145.99 on Tuesday. The firm has a market cap of $11.68 billion, a P/E ratio of 13.59, a price-to-earnings-growth ratio of 1.01 and a beta of 0.94. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18. DaVita has a 1-year low of $119.42 and a 1-year high of $179.60. The business’s 50 day moving average is $161.24 and its 200-day moving average is $157.81.

DaVita (NYSE:DVA) last issued its earnings results on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating analysts’ consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. Equities research analysts predict that DaVita will post 10.72 earnings per share for the current year.

Institutional Trading of DaVita

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Transcendent Capital Group LLC bought a new stake in DaVita during the 3rd quarter worth approximately $25,000. SBI Securities Co. Ltd. purchased a new position in DaVita in the fourth quarter valued at approximately $41,000. Coppell Advisory Solutions LLC raised its holdings in DaVita by 50.0% during the 4th quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company’s stock valued at $45,000 after acquiring an additional 100 shares during the period. Blue Trust Inc. raised its holdings in DaVita by 56.4% during the 3rd quarter. Blue Trust Inc. now owns 330 shares of the company’s stock valued at $54,000 after acquiring an additional 119 shares during the period. Finally, Canada Post Corp Registered Pension Plan bought a new stake in DaVita during the 4th quarter valued at $55,000. 90.12% of the stock is owned by institutional investors.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.